|
|
SAKK24/09
| Third-party funded project |
| Project title |
SAKK24/09 |
| Principal Investigator(s) |
Thürlimann, Beat
|
| Organisation / Research unit |
Bereich Medizinische Fächer (Klinik) / Onkologie |
| Project start |
01.07.2010 |
| Probable end |
31.12.2010 |
| Status |
Completed |
| Abstract |
Safety and tolerability of bevacizumab plus paxlitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecetabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase lll trial. |
| Financed by |
Private Sector / Industry
|
| |
|
|
MCSS v5.8 PRO. 0.460 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
04/05/2024
Research Database / FORSCHUNGSDATENBANK
|
